MCL Literature Feed

In real-world relapsed/refractory MCL, ibrutinib dose reduction to manage toxicity is common and does not compromise response rates, PFS, or OS, validating this as a practical clinical strategy.

This case report details severe, reversible myocarditis from bortezomib, a rare but critical cardiotoxicity for clinicians to recognize in MCL patients receiving proteasome inhibitor-based therapy.

This review contextualizes MCL-approved BTK inhibitors by summarizing their distinct covalent and non-covalent binding mechanisms, which underlie differences in efficacy, toxicity, and overcoming resistance.

Real-world data from Germany and Switzerland confirms the effectiveness of brexucabtagene-autoleucel in relapsed/refractory MCL, supporting its use in routine clinical practice beyond trial populations.

This UK real-world study shows chemotherapy bridging before brexu-cel yields higher responses than targeted therapy but causes more toxicity and early mortality without improving post-CAR-T survival.

Brexucabtagene autoleucel demonstrates high efficacy (91% ORR, 73% CR) in BTKi-naive relapsed/refractory MCL, supporting its use as an effective option before BTKi failure in high-risk patients.

The novel BCL-2 inhibitor lisaftoclax demonstrated a 50% overall response rate and manageable safety in a phase 1 trial of Chinese patients with relapsed/refractory MCL.

In a real-world R/R MCL cohort, zanubrutinib demonstrated significantly longer overall survival versus ibrutinib and favorable trends versus acalabrutinib, guiding clinical selection of covalent BTKis.

In a large real-world cohort, brexu-cel demonstrated high efficacy in R/R MCL patients ≥70 years, indicating functional status, not chronological age, should determine CAR-T eligibility.

The oral AKT inhibitor capivasertib showed modest single-agent activity (30% ORR) in relapsed/refractory MCL, with PTEN deficiency emerging as a potential predictive biomarker for patient selection.

A case report demonstrates repeated MCL progression upon initiation of the JAK-1 inhibitor upadacitinib for psoriatic arthritis, suggesting a potential role for JAK signaling in promoting MCL growth.

This large real-world study shows second primary malignancies in MCL patients double mortality risk versus non-MCL patients, mandating long-term surveillance for these subsequent cancers.

This case report details pleomorphic MCL presenting as life-threatening hemophagocytic lymphohistiocytosis (HLH), emphasizing the need for high clinical suspicion of this rare, sepsis-mimicking oncologic emergency.

This paper details a new UPLC-MS/MS method for rapid venetoclax plasma quantification, which could facilitate therapeutic drug monitoring to optimize dosing and toxicity management in MCL.

The CD19 CAR-T therapy relma-cel demonstrated high, durable responses (71% ORR, 18-month DOR) with manageable toxicity in heavily pretreated Chinese patients, establishing it as an effective option for relapsed/refractory MCL.

In a retrospective ZUMA-2 analysis, prior ibrutinib exposure, versus acalabrutinib, improved brexu-cel CAR-T efficacy and PFS by inducing a more favorable cytotoxic T-cell phenotype.

This case report identifies fingertip fissures as a rare dermatologic toxicity of ibrutinib in an elderly MCL patient, expanding the known adverse event profile for this common therapy.

This review positions CAR-T and bispecific antibodies as complementary tools for relapsed/refractory MCL, advocating for individualized sequencing and combinations to optimize outcomes in heavily pretreated, high-risk patients.

This meta-analysis quantifies the high incidence of neurotoxicity (ICANS) with brexucabtagene autoleucel in MCL, finding 61% of patients experience any grade and 33% experience severe events.

This review summarizes cutaneous toxicities across different BTK inhibitors, highlighting the improved skin safety profile of newer agents, which is critical for managing long-term MCL therapy.

This case report details a rare MCL-induced paraneoplastic 'full-house' nephropathy mimicking lupus nephritis, which resolved with lymphoma-directed therapy, expanding the spectrum of known renal complications.

This review highlights the improved cardiovascular safety of next-generation BTK inhibitors over ibrutinib, which is critical for MCL treatment selection and long-term management of associated cardiac toxicities.

This preclinical mouse study shows zanubrutinib mitigates pulmonary fibrosis by inhibiting the Wnt/β-catenin pathway, a novel off-target mechanism potentially relevant to managing toxicities in MCL patients.

Emapalumab, an interferon-gamma blocker, successfully treated severe immune effector cell-associated HLH-like syndrome (IEC-HS) in a relapsed MCL patient post-CAR-T, offering a targeted approach for this life-threatening toxicity.

This paper on rhinosinusitis in a general post-transplant population is not specific to mantle cell lymphoma and provides no new insights for the MCL field.

Nintedanib rapidly reversed severe, steroid-resistant post-COVID-19 lung fibrosis in an immunocompromised mantle cell lymphoma patient, highlighting a potential therapy for this specific respiratory complication.

This case report identifies ANCA-positive pauci-immune glomerulonephritis as a rare initial presentation of MCL, emphasizing the need to consider underlying malignancy in patients with this renal pathology.

Prophylactic siltuximab, guided by rising CRP, effectively managed cytokine release syndrome from bispecifics while minimizing infections by avoiding corticosteroids, a promising toxicity management strategy for MCL patients.

This case report describes an early-onset disseminated adenovirus infection after CAR-T therapy for relapsed/refractory MCL, highlighting a critical and potentially fatal infectious toxicity of this cellular therapy.

This case report links the next-generation BTKi orelabrutinib to multiple skin cancers, suggesting this toxicity may be a class effect and reinforcing the need for dermatologic surveillance.